首页> 美国卫生研究院文献>Molecular Medicine Reports >Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells
【2h】

Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells

机译:改进的疏肝凉血汤联合阿那曲唑对成骨细胞增殖和分化的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aromatase inhibitors (AIs) are widely used in the treatment of hormone-dependent breast cancer and as a result, aromatase inhibitor-associated bone loss (AIBL) has become a major concern amongst patients receiving AI treatment. Modified Shu-Gan-Liang-Xue decoction (mSGLXD), a clinical prescription, has been used for ameliorating AIBL in patients with breast cancer for decades and has achieved good clinical efficacy. However, the mechanism underlying how mSGLXD influences bone homeostasis and alleviates AIBL has remained elusive. In the present study, mSGLXD was supplemented with Rhizoma Drynariae containing phytoestrogens, and the safety of mSGLXD was evaluated. mSGLXD did not possess estrogenic activity and significantly inhibited the proliferation of estrogen receptor-positive breast cancer cell line MCF-7, which suggested that mSGLXD was safe for postmenopausal patients with breast cancer. Subsequently, the effects of mSGLXD alone or in combination with anastrozole on osteoblastic MC3T3-E1 cell proliferation and differentiation were investigated. Cell counting kit-8, reverse transcription-polymerase chain reaction and biochemical methods, such as ELISA and alizarin red S staining, were used in the present study. It was revealed that mSGLXD not only stimulated MC3T3-E1 cell proliferation, but also upregulated alkaline phosphatase and osteocalcin gene and protein expression levels. High concentrations of anastrozole (10 or 100 μmol/l) markedly inhibited MC3T3-E1 cell proliferation, but this inhibitory effect was attenuated by mSGLXD. Furthermore, mSGLXD increased MC3T3-E1 cell mineralization following β-glycerophosphate and ascorbic acid induction. Therefore, the results of the present study suggested that mSGLXD may be a promising adjuvant therapy, with high safety and efficacy, for the prevention and treatment of AIBL in patients with breast cancer who receive AI treatment.
机译:芳香酶抑制剂(AIs)被广泛用于激素依赖性乳腺癌的治疗,结果,与芳香酶抑制剂相关的骨丢失(AIBL)已成为接受AI治疗的患者中的主要问题。改良的Shu-Gan-Liang-Xue汤(mSGLXD)是一种临床处方,已被用于改善乳腺癌患者的AIBL数十年,并取得了良好的临床疗效。但是,mSGLXD如何影响骨骼稳态并减轻AIBL的潜在机制仍然难以捉摸。在本研究中,mSGLXD补充了含有植物雌激素的马鞭草,并评估了mSGLXD的安全性。 mSGLXD不具有雌激素活性,并且显着抑制雌激素受体阳性乳腺癌细胞MCF-7的增殖,这表明mSGLXD对于绝经后乳腺癌患者是安全的。随后,研究了单独或与阿那曲唑合用的mSGLXD对成骨细胞MC3T3-E1细胞增殖和分化的影响。本研究使用细胞计数试剂盒8,逆转录聚合酶链反应和生化方法,如ELISA和茜素红S染色。结果表明,mSGLXD不仅刺激MC3T3-E1细胞增殖,而且上调碱性磷酸酶和骨钙素基因及蛋白表达水平。高浓度的阿那曲唑(10或100μmol/ l)明显抑制MC3T3-E1细胞增殖,但这种抑制作用被mSGLXD减弱。此外,在β-甘油磷酸和抗坏血酸诱导后,mSGLXD增加了MC3T3-E1细胞的矿化作用。因此,本研究结果表明,mSGLXD可能是一种有前途的辅助疗法,具有很高的安全性和有效性,可用于预防和治疗接受AI治疗的乳腺癌患者的AIBL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号